Cover Image
市場調查報告書

Frontier Pharma:慢性·急性·神經病變性疼痛 - 基於GPCR·NGF之治療

Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes

出版商 GBI Research 商品編碼 369231
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
Frontier Pharma:慢性·急性·神經病變性疼痛 - 基於GPCR·NGF之治療 Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes
出版日期: 2016年08月01日 內容資訊: 英文 68 Pages
簡介

本報告提供慢性·急性·神經病變性疼痛治療藥市場相關調查分析,提供革新案例,臨床·商業性情形,開發中產品的評估,計劃評估,最近的交易等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 革新案例

  • 生技藥品的機會擴大
  • 分子標的多樣化
  • 創新的First-in-Class產品 (劃時代醫藥品)的開發現在極具吸引力
  • 法規·給付政策對First-in-Class產品的革新有利
  • 持續性的革新
  • 報告指南

第4章 臨床·商業性情形

  • 疾病概要
  • 疼痛治療藥的上市產品概要

第5章 慢性·急性·神經病變性疼痛治療藥的開發中產品革新性評估

  • 疼痛治療藥開發平台:分子類型,開發階段,分子標的別
  • 疼痛治療藥市場與開發平台間的計劃比較分佈:各治療標的系列
  • First-in-Class開發平台計劃
  • First-in-Class·現有的開發中產品:疼痛治療藥各子類型
  • First-in-Class疼痛治療藥開發平台全產品

第6章 疼痛的病理生理學與創新的調整

  • 中樞神經系統的信號傳達網路的複雜
  • 矩陣的評估

第7章 First-in-Class目標與開發平台計劃的評估

第8章 與交易策略性整合

  • 產業整體First-in-Class交易
  • 疼痛治療藥的交易形勢
  • 授權交易
  • 共同開發交易
  • 非授權/共同開發交易的開發中產品清單

第9章 附錄

圖表

目錄
Product Code: GBIHC356MR

Pain is a complex and multifaceted disorder with a complex interplay between different pathological processes, and different pain subtypes exhibiting distinct underlying etiologies and patho-physiologies. While technological advances and extensive research efforts have furthered the understanding of the pathophysiology of these complex indications, substantial gaps in scientific knowledge remain.

Pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established product categories, active pharmaceutical ingredients and concomitant mechanisms of action. Patent applications for novel pain therapeutics declined steadily in number from 4,970 in 2008 to 3,492 in 2012, an average annual decrease of 8%, as limited understanding of pain pathophysiology continues to hinder drug development in this arena.

The active pain pipeline is populated by 810 products across all stages of development, which exhibit a highly diverse range of molecular targets. It is identified that 129 first-in-class programs in active development, constituting 20% of the pipeline for which there is a disclosed molecular target, and acting on 80 first-in-class molecular targets.

Global pain treatment market is dominated by opioids and steroidal anti-inflammatory drugs, with no novel products currently able to challenge these products' efficacy in treating moderate to severe acute pain. Furthermore, despite the significant unmet needs for more effective therapies in other pain subtypes, such as chronic and neuropathic pain, due to their rising prevalence, the factors underpinning these subtypes are complex and poorly understood.

The report "Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes" provides a brief analysis of innovation in the pain markets (including both nociceptive and neuropathic pain, of both a chronic and acute nature), in the context of the overall pipeline and current market landscape.

In depth, it provides the following:

  • Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
  • Helps to identify and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
  • Analysis of the deals landscape surrounding first-in-class products in pain, and highlights opportunities for in-licensing.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Executive Summary

  • 2.1. Substantial Unmet Needs Remain in Core Therapy Types
  • 2.2. Highly Diversified Range of Innovative Programs in Early Pipeline
  • 2.3. Rich Pipeline Landscape with Numerous Investment Opportunities

3. The Case for Innovation

  • 3.1. Growing Opportunities for Biologic Products
  • 3.2. Diversification of Molecular Targets
  • 3.3. Innovative First-in-Class Product Development Remains Attractive
  • 3.4. Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
  • 3.5. Sustained Innovation
  • 3.6. GBI Research Report Guidance

4. Clinical and Commercial Landscape

  • 4.1. Disease Overview
    • 4.1.1. Chronic and Neuropathic Pain
    • 4.1.2. Disease Pathophysiology
    • 4.1.3. Diagnosis
    • 4.1.4. Treatment Options
  • 4.2. Overview of Marketed Products for Pain
    • 4.2.1. Analgesic Product Categories
    • 4.2.2. Molecular Type Analysis
    • 4.2.3. Current Unmet Needs

5. Assessment of Pipeline Product Innovation in Chronic, Acute and Neuropathic Pain

  • 5.1. Pain Pipeline by Molecule Type, Stage of Development and Molecular Target
  • 5.2. Comparative Distribution of Programs between the Pain Market and Pipeline by Therapeutic Target Family
  • 5.3. First-in-Class Pipeline Programs
  • 5.4. First-in-Class and Established Pipeline Products by Pain Subtype
  • 5.5. Table of All First-in-Class Pain Pipeline Products

6. Pain Pathophysiology and Innovation Alignment

  • 6.1. The Complexity of Signaling Networks in the Central Nervous System
  • 6.2. Matrix Assessment

7. First-in-Class Target and Pipeline Program Evaluation

  • 7.1. Pipeline Programs Targeting Nerve Growth Factor and High Affinity Nerve Growth Factor Receptor
  • 7.2. Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 16
  • 7.3. Pipeline Programs Targeting Bradykinin B1 Receptor
  • 7.4. Pipeline Programs Targeting Opioid Receptor-Like-1 Receptor
  • 7.5. Pipeline Programs Targeting Purinoceptor 7
  • 7.6. Pipeline Programs Targeting Metabotropic Glutamate Receptors 6 and 7
  • 7.7. Pipeline Programs Targeting Calcitonin Gene-Related Peptide Type-1 Receptor

8. Deals and Strategic Consolidations

  • 8.1. Industry-Wide First-in-Class Deals
  • 8.2. Pain Deals Landscape
  • 8.3. Licensing Deals
    • 8.3.1. Molecule Type
    • 8.3.2. Mechanism of Action
  • 8.4. Co-development Deals
    • 8.4.1. Molecule Type
    • 8.4.2. Mechanism of Action
  • 8.5. List of Pipeline Products without Prior Licensing or Co-Development Deal Involvement

9. Appendix

  • 9.1. Abbreviations
  • 9.2. References
  • 9.3. Contact Us
  • 9.4. Disclaimer

List of Tables

  • Table 1: Pain Market, Global, Categories of Pain, 2016
  • Table 2: Pain Market, Global, Data for Nerve Growth Factor as a Molecular Target, 2016
  • Table 3: Pain Market, Global, Data for High Affinity Nerve Growth Factor Receptor as a Molecular Target, 2016
  • Table 4: Pain Market, Global, Data for Tumor Necrosis Factor Receptor Superfamily Member 16 as a Molecular Target, 2016
  • Table 5: Pain Market, Global, Data for Bradykinin B1 Receptor as a Molecular Target, 2016
  • Table 6: Pain Market, Global, Data for Opioid Receptor-Like-1 Receptor as a Molecular Target, 2016
  • Table 7: Pain Market, Global, Data for Purinoceptor 7 as a Molecular Target, 2016
  • Table 8: Pain Market, Global, Data for Metabotropic Glutamate Receptor 6 as a Molecular Target, 2016
  • Table 9: Pain Market, Global, Data for Metabotropic Glutamate Receptor 7 as a Molecular Target, 2016
  • Table 10: Pain Market, Global, Data for Calcitonin Gene-Related Peptide Type-1 Receptor as a Molecular Target, 2016

List of Figures

  • Figure 1: Pharmaceutical Market, Global, Innovation Trends in Product Approvals, 1987-2012
  • Figure 2: Pharmaceutical Market, Global, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013
  • Figure 3: Pain Market, Global, Treatment Algorithm
  • Figure 4: Pain Market, Global, WHO Analgesic Ladder
  • Figure 5: Pain Market, Global, Marketed Products by Molecule Type and Molecular Target, 2016
  • Figure 6: Pharmaceutical Market, Global, Developmental Pipeline Overview, 2016
  • Figure 7: Pain Market, Global, Developmental Pipeline Overview, 2016
  • Figure 8: Pain Market, Global, Developmental Pipeline Molecular Target Categories, 2016
  • Figure 9: Pain Market, Global, Molecular Target Category Comparison of Pipeline and Marketed Products, 2016
  • Figure 10: Pain Market, Global, Molecular Target Category Comparison of Pipeline First-in-Class and Established Molecular Targets, 2016
  • Figure 11: Pain Market, Global, Level of First-in-Class Innovation by Stage of Development (%), 2016
  • Figure 12: Pain Market, Global, Level of First-in-Class Innovation by Molecular Target (%), 2016
  • Figure 13: Pain Market, Global, Total Pipeline Products by Pain Subtype and Stage of Development, 2016
  • Figure 14: Pain Market, Global, Total Pipeline Products by Pain Subtype and Stage of Development, 2016
  • Figure 15: Pain Market, Global, First-in-Class Pipeline Products by Pain Subtype and Molecular Target, 2016
  • Figure 16: Pain Market, Global, First-in-Class Pipeline Products by Pain Subtype and Stage of Development, 2016
  • Figure 17: Pain Market, Global, First-in-Class Products in the Pipeline Part 1, 2016
  • Figure 18: Pain Market, Global, First-in-Class Products in the Pipeline Part 2, 2016
  • Figure 19: Pain Market, Global, First-in-Class Molecular Target Analysis Matrix Part 1, 2016
  • Figure 20: Pain Market, Global, First-in-Class Molecular Target Analysis Matrix Part 2, 2016
  • Figure 21: Pain Market, Global, Pipeline Programs Targeting Nerve Growth Factor, 2016
  • Figure 22: Pain Market, Global, Pipeline Programs Targeting High Affinity Nerve Growth Factor Receptor, 2016
  • Figure 23: Pain Market, Global, Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 16, 2016
  • Figure 24: Pain Market, Global, Pipeline Programs Targeting Bradykinin B1 Receptor, 2016
  • Figure 25: Pain Market, Global, Pipeline Programs Targeting Opioid Receptor-Like-1 Receptor, 2016
  • Figure 26: Pain Market, Global, Pipeline Programs Targeting Purinoceptor 7, 2016
  • Figure 27: Pain Market, Global, Pipeline Programs Targeting Glutamate Receptor 6, 2016
  • Figure 28: Pain Market, Global, Pipeline Programs Targeting Glutamate Receptor 7, 2016
  • Figure 29: Pain Market, Global, Pipeline Programs Targeting Calcitonin Gene-Related Peptide Type-1 Receptor, 2016
  • Figure 30: Pharmaceutical Market, Global, Industry-Wide Deals by Stage of Development, 2006-2014
  • Figure 31: Pharmaceutical Market, Global, Industry Licensing Deal Values by Stage of Development, 2006-2014
  • Figure 32: Pain Market, Global, Licensing Deals by Region and Value, 2006-2016
  • Figure 33: Pain Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016
  • Figure 34: Pain Market, Global, Licensing Deals by Stage of Development and Molecule Type, 2006-2016
  • Figure 35: Pain Market, Global, Licensing Deals by Stage of Development and Molecular Target, 2006-2016
  • Figure 36: Pain Market, Global, Summary of Licensing Deals Valued Above $100m, 2006-2016
  • Figure 37: Pain Market, Global, Co-development Deals by Region and Value, 2006-2015
  • Figure 38: Pain Market, Global, Co-Development Deals by Stage of Development and Value, 2006-2016
  • Figure 39: Pain Market, Global, Co-Development Deals by Stage of Development and Molecule Type, 2006-2016
  • Figure 40: Pain Market, Global, Co-Development Deals by Stage of Development and Molecular Target, 2006-2016
  • Figure 41: Pain Market, Global, Summary of Co-development Deals Valued Above $100m, 2006-2016
  • Figure 42: Pain Market, Global, List of Pipeline Products With Prior Licensing or Co-Development Deal Involvement, 2016
  • Figure 43: Pain Market, Global, List of Pipeline Products Without Prior Licensing or Co-Development Deal Involvement, 2016
Back to Top